Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors

BACKGROUND: BI 836880 is a humanized bispecific nanobody® that inhibits vascular endothelial growth factor and angiopoietin-2. Here, we report results from two phase I, nonrandomized, dose-escalation studies (NCT02674152 and NCT02689505; funded by Boehringer Ingelheim) evaluating BI 836880 in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Le Tourneau, C., Becker, H., Claus, R., Elez, E., Ricci, F., Fritsch, R., Silber, Y., Hennequin, A., Tabernero, J., Jayadeva, G., Luedtke, D., He, M., Isambert, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588896/
https://www.ncbi.nlm.nih.gov/pubmed/36108560
http://dx.doi.org/10.1016/j.esmoop.2022.100576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588896/
https://www.ncbi.nlm.nih.gov/pubmed/36108560
http://dx.doi.org/10.1016/j.esmoop.2022.100576

Ejemplares similares